Brief: Virpax® Pharmaceuticals Receives FDA Response And Guidance On Mms019

Virpax Pharmaceuticals

17/08/2021 14:18

Aug 17 (Reuters) - Virpax Pharmaceuticals Inc  VRPX.O :
    * VIRPAX® PHARMACEUTICALS RECEIVES FDA RESPONSE AND GUIDANCE
ON
MMS019
    * VIRPAX PHARMACEUTICALS INC - CO TO PURSUE PROPHYLACTIC
TREATMENT
AGAINST SARS AND INFLUENZA FOR DAILY USE AS AN OTC PRODUCT
    * VIRPAX PHARMACEUTICALS INC - RECEIVED WRITTEN
PRE-INVESTIGATIONAL NEW DRUG RESPONSE FROM U.S. FDA FOR MMS019
    * VIRPAX PHARMACEUTICALS INC - FDA HAS INDICATED THAT CO MAY
PURSUE AN NDA DRUG APPROVAL WITH OFFICE OF NON-PRESCRIPTION
DRUGS
    * VIRPAX - RESULTS OF PRE-IND RESPONSE SUPPORT FURTHER
RESEARCH ON
MMS019 AS AN INTRANASAL PROTECTIVE THAT MAY LIMIT TRANSMISSION
OF VIRUSES TO OTHERS
    * VIRPAX PHARMACEUTICALS INC - ENGAGED SYNEOS HEALTH TO
ASSIST
WITH OPTIMAL CLINICAL TRIAL DESIGN FOR MMS019 BASED ON AN
EFFICIENT TIMELINE
    * VIRPAX PHARMACEUTICALS INC - EXPECTS TO MOVE FORWARD AND
PURSUE
A NDA FOR MMS019 AS A ONCE DAILY INTRANASAL TREATMENT

Source text for Eikon:  ID:nBw11VJ7Xa 
Further company coverage:  VRPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))